Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of salvianolic acid B and its salt in treating parkinson's disease

A technology for Parkinson's disease and salvianolic acid, applied to salvianolic acid B and its salts in the field of treating Parkinson's disease, can solve problems such as inability to achieve therapeutic effects, inconvenience in use, etc., and achieve improved cerebral blood flow and safety. The effect of high sex and improving the quality of life

Inactive Publication Date: 2008-08-13
INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
View PDF13 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the side effects or inconvenient use of these drugs, satisfactory therapeutic effects cannot yet be achieved. Finding and developing new drugs for the treatment or prevention of Parkinson's disease has significant social and economic benefits

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of salvianolic acid B and its salt in treating parkinson's disease
  • Use of salvianolic acid B and its salt in treating parkinson's disease
  • Use of salvianolic acid B and its salt in treating parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] [Example 1] Salvianolic acid B cytotoxicity detection

[0025] Materials and Methods

[0026] 1. SH-SY5Y cell culture

[0027] SH-SY5Y cells were cultured in a DMEM medium containing 10% fetal bovine serum (Gibco), 100 IU / ml penicillin, and 100 g / ml streptomycin at 37°C in a 5% CO2 incubator. Observe that the cells are in a good growth state. After culturing to the logarithmic growth phase, inoculate SH-SY5Y cells in a 96-well plate, 2×105 cells / well, and incubate at 37°C, 5% CO2 for 24 hours, until 80-90% of the cells are confluent Afterwards, the dosing experiment was carried out.

[0028] 2. Effect of salvianolic acid B on the proliferation of SH-SY5Y cells

[0029] SH-SY5Y cells were cultured in DMEM medium containing 10% fetal bovine serum (Gibco), 100 IU / ml penicillin, and 100 g / ml in a 37°C, 5% CO2 incubator. Observe that the cells are in a good growth state. After culturing to the logarithmic growth phase, inoculate SH-SY5Y cells in a 96-well plate, 2×105 ce...

Embodiment 2

[0036] [Example 2] The effect of salvianolic acid B on the loss of viability of SH-SY5Y cells caused by 6-hydroxydopamine (6-OHDA)

[0037] Materials and Methods

[0038] 1. SH-SY5Y cell culture

[0039] Method sees embodiment one

[0040] 2. Detection of the effect of salvianolic acid B on the loss of viability of SH-SY5Y cells induced by 6-hydroxydopamine (6-OHDA)

[0041] SH-SY5Y cells were cultured in DMEM medium containing 10% fetal bovine serum (Gibco), 100 IU / ml penicillin, and 100 g / ml in a 37°C, 5% CO2 incubator. Observe that the cells are in a good growth state. After culturing to the logarithmic growth phase, inoculate SH-SY5Y cells in a 96-well plate, 2×105 cells / well, and incubate at 37°C, 5% CO2 for 24 hours, until 80-90% of the cells are confluent Afterwards, one of the groups administered the compound salvianolic acid B at a final concentration of 2.5 μM / L, 5 μM / L, and 10 μM / L, respectively, with 3 wells for each concentration, and then administered 6-hydrox...

Embodiment 3

[0048] [Example 3] Detection of the impact of salvianolic acid B on striatal dopamine content in Parkinson's disease rat model

[0049] Materials and Methods

[0050] 1. SD rat culture

[0051]40 healthy adult male SD rats, weighing between 200 and 300 g, were selected and provided by the Animal Experiment Center of the Academy of Military Medical Sciences. Rats were kept at an ambient temperature of 25°C.

[0052] 2. Detection of the effect of salvianolic acid B on striatal dopamine content in Parkinson's disease rat model

[0053] Parkinson's rat model production: directional injection of micro-6-OHDA method: intraperitoneal injection of 3% (ω) pentobarbital sodium (30mg / kg) to anesthetize the rat, and fix the head of the rat on the brain stereotaxic apparatus , The anterior and posterior fontanelles are even, exposing the skull and cleaning the bone surface. According to the Paxinos and Watson rat brain stereotaxic atlas, the coordinates of the substantia nigra compact ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a new usage of Salvianolic acid B and the salt used in curing parkinsonism, the usages of the medicine combined material of the Salvianolic acid B as well as the salt, and the medicine combined material or each unit being jointly used with other current medicines curing parkinsonism used for curing parkinsonism.

Description

technical field [0001] The invention relates to the use of salvianolic acid B and its salts in treating Parkinson's disease. Background technique [0002] Salvia miltiorrhiza is a commonly used drug in traditional medicine in my country, and it is mainly used in the treatment of cardiovascular and cerebrovascular diseases and various related diseases in clinical practice. Salvianolic acid B is the main active ingredient of Salvia miltiorrhiza, with high content and strong efficacy. Extensive research has been done on its application in the prior art. [0003] Known possible medical uses of salvianolic acid B include: [0004] 1. Cardiovascular and cerebrovascular diseases, including coronary heart disease, angina pectoris, heart failure, arrhythmia, cerebral infarction, cerebral ischemia, etc. See Chinese patents 99112300.X, 02155004.2, 200410026913.7, 200410048799.8. [0005] 2. Anti-tumor. See Chinese patents 02136970.4 and 200510028311.X. [0006] 3. Anti-fibrotic di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61K9/08A61K9/20A61K9/48A61P25/16
Inventor 王升启田琳琳周喆贾高龙赵海豹邢雅玲叶志华
Owner INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com